194 related articles for article (PubMed ID: 26139427)
1. Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia.
Ghobrial IM; Redd R; Armand P; Banwait R; Boswell E; Chuma S; Huynh D; Sacco A; Roccaro AM; Perilla-Glen A; Noonan K; MacNabb M; Leblebjian H; Warren D; Henrick P; Castillo JJ; Richardson PG; Matous J; Weller E; Treon SP
Leukemia; 2015 Dec; 29(12):2338-46. PubMed ID: 26139427
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
Ghobrial IM; Hong F; Padmanabhan S; Badros A; Rourke M; Leduc R; Chuma S; Kunsman J; Warren D; Harris B; Sam A; Anderson KC; Richardson PG; Treon SP; Weller E; Matous J
J Clin Oncol; 2010 Mar; 28(8):1422-8. PubMed ID: 20142586
[TBL] [Abstract][Full Text] [Related]
3. Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214).
Treon SP; Meid K; Tripsas C; Heffner LT; Eradat H; Badros AZ; Xu L; Hunter ZR; Yang G; Patterson CJ; Gustine J; Castillo JJ; Matous J; Ghobrial IM
Clin Cancer Res; 2017 May; 23(10):2400-2404. PubMed ID: 27836860
[No Abstract] [Full Text] [Related]
4. Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.
Kapoor P; Ansell SM; Fonseca R; Chanan-Khan A; Kyle RA; Kumar SK; Mikhael JR; Witzig TE; Mauermann M; Dispenzieri A; Ailawadhi S; Stewart AK; Lacy MQ; Thompson CA; Buadi FK; Dingli D; Morice WG; Go RS; Jevremovic D; Sher T; King RL; Braggio E; Novak A; Roy V; Ketterling RP; Greipp PT; Grogan M; Micallef IN; Bergsagel PL; Colgan JP; Leung N; Gonsalves WI; Lin Y; Inwards DJ; Hayman SR; Nowakowski GS; Johnston PB; Russell SJ; Markovic SN; Zeldenrust SR; Hwa YL; Lust JA; Porrata LF; Habermann TM; Rajkumar SV; Gertz MA; Reeder CB
JAMA Oncol; 2017 Sep; 3(9):1257-1265. PubMed ID: 28056114
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia.
Ghobrial IM; Witzig TE; Gertz M; LaPlant B; Hayman S; Camoriano J; Lacy M; Bergsagel PL; Chuma S; DeAngelo D; Treon SP
Am J Hematol; 2014 Mar; 89(3):237-42. PubMed ID: 24716234
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.
Ghobrial IM; Xie W; Padmanabhan S; Badros A; Rourke M; Leduc R; Chuma S; Kunsman J; Warren D; Poon T; Harris B; Sam A; Anderson KC; Richardson PG; Treon SP; Weller E; Matous J
Am J Hematol; 2010 Sep; 85(9):670-4. PubMed ID: 20652865
[TBL] [Abstract][Full Text] [Related]
7. A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone.
Leblond V; Morel P; Dilhuidy MS; Leleu X; Soussain C; Leprête S; Dreyfus B; Dartigeas C; Mahé B; Anglaret B; Pégourié B; Besson C; Aurran T; Vekhoff A; Tournilhac O; Banos A; Oya H; Lejeune J; Ouzegdouh M; Chevret S;
Leuk Lymphoma; 2017 Nov; 58(11):2615-2623. PubMed ID: 28395585
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.
Ghobrial IM; Gertz M; Laplant B; Camoriano J; Hayman S; Lacy M; Chuma S; Harris B; Leduc R; Rourke M; Ansell SM; Deangelo D; Dispenzieri A; Bergsagel L; Reeder C; Anderson KC; Richardson PG; Treon SP; Witzig TE
J Clin Oncol; 2010 Mar; 28(8):1408-14. PubMed ID: 20142598
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia.
Roccaro AM; Sacco A; Jia X; Banwait R; Maiso P; Azab F; Flores L; Manier S; Azab AK; Ghobrial IM
Clin Cancer Res; 2012 Dec; 18(24):6609-22. PubMed ID: 23048077
[TBL] [Abstract][Full Text] [Related]
10. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
[TBL] [Abstract][Full Text] [Related]
11. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
Paludo J; Abeykoon JP; Shreders A; Ansell SM; Kumar S; Ailawadhi S; King RL; Koehler AB; Reeder CB; Buadi FK; Dispenzieri A; Lacy MQ; Dingli D; Witzig TE; Go RS; Gonsalves WI; Kourelis T; Warsame R; Leung N; Habermann TM; Hayman S; Lin Y; Kyle RA; Rajkumar SV; Gertz MA; Kapoor P
Ann Hematol; 2018 Aug; 97(8):1417-1425. PubMed ID: 29610969
[TBL] [Abstract][Full Text] [Related]
12. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).
Dimopoulos MA; García-Sanz R; Gavriatopoulou M; Morel P; Kyrtsonis MC; Michalis E; Kartasis Z; Leleu X; Palladini G; Tedeschi A; Gika D; Merlini G; Kastritis E; Sonneveld P
Blood; 2013 Nov; 122(19):3276-82. PubMed ID: 24004667
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
[TBL] [Abstract][Full Text] [Related]
15. How I treat Waldenström macroglobulinemia.
Treon SP
Blood; 2015 Aug; 126(6):721-32. PubMed ID: 26002963
[TBL] [Abstract][Full Text] [Related]
16. Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.
Dimopoulos MA; Anagnostopoulos A; Kyrtsonis MC; Castritis E; Bitsaktsis A; Pangalis GA
Haematologica; 2005 Dec; 90(12):1655-8. PubMed ID: 16330439
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
[TBL] [Abstract][Full Text] [Related]
18. Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia.
Castillo JJ; Gustine JN; Keezer A; Meid K; Flynn CA; Dubeau TE; Chan G; Chen J; Demos MG; Guerrera ML; Jimenez C; Kofides A; Liu X; Munshi M; Tsakmaklis N; Patterson CJ; Xu L; Yang G; Hunter ZR; Treon SP
Am J Hematol; 2020 Apr; 95(4):372-378. PubMed ID: 31868242
[TBL] [Abstract][Full Text] [Related]
19. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
Buske C; Tedeschi A; Trotman J; García-Sanz R; MacDonald D; Leblond V; Mahe B; Herbaux C; Matous JV; Tam CS; Heffner LT; Varettoni M; Palomba ML; Shustik C; Kastritis E; Treon SP; Ping J; Hauns B; Arango-Hisijara I; Dimopoulos MA
J Clin Oncol; 2022 Jan; 40(1):52-62. PubMed ID: 34606378
[TBL] [Abstract][Full Text] [Related]
20. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.
Dimopoulos MA; Anagnostopoulos A; Kyrtsonis MC; Zervas K; Tsatalas C; Kokkinis G; Repoussis P; Symeonidis A; Delimpasi S; Katodritou E; Vervessou E; Michali E; Pouli A; Gika D; Vassou A; Terpos E; Anagnostopoulos N; Economopoulos T; Pangalis G
J Clin Oncol; 2007 Aug; 25(22):3344-9. PubMed ID: 17577016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]